Promising lymphoma combo study pulled before starting
Disease control
Terminated
This study was designed to see if adding tazemetostat to standard CHOP chemotherapy could improve outcomes for people with untreated peripheral T cell lymphoma. It was withdrawn before any participants enrolled, so no results are available. The goal was to increase the number of …
Phase: PHASE2 • Sponsor: Eric Jacobsen, MD • Aim: Disease control
Last updated May 17, 2026 03:26 UTC